Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
References AUTM (Association of University Technology Managers). 2007. Nine points to consider in licensing university technology. http://www.autm.net/aboutTT/Points_to_Consider.pdf (accessed October 8, 2008). Bromley, R. 2008. Accelerating IP sharing to facilitate translation. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Bryce, J., C. Boschi-Pinto, K. Shibuya, R. E. Black, and the WHO Child Health ÂEpidemiology Reference Group. 2005. WHO estimates of the causes of death in children. Lancet 365(9465):1147â1152. Caskey, C. T. 2007. The drug development crisis: Efficacy and safety. Annual Review of Medicine 58:1â16. Cohen, J. 2008. HIV/AIDS. Bang for the buck. Science 321(5888):518â519. Corr, P. 2008. New business models addressing global health: A framework for private equity. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Coté, T. 2008. Building on success: Lessons from the Orphan Drug Act. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Daviss, B. 2005. Malaria, science, and social responsibility. The Scientist 19(6):42. Dilts, D. M., and A. B. Sandler. 2006. Invisible barriers to clinical trials: The impact of struc- tural, infrastructural, and procedural barriers to opening oncology clinical trials. Journal of Clinical Oncology 24(28):4545â4552. FitzGerald, G. 2008. Drugs, industry, and academia. Science 320(5883):1563. Gambrill, S. 2007. Venture philanthropy on the rise. The CenterWatch Monthly 14(8):6â14. IOM (Institute of Medicine). 2001. Small clinical trials: Issues and challenges. Washington, DC: National Academy Press. Mimura, C. 2006. Technology licensing for the benefit of the developing world: UC Berkeleyâs Socially Responsible Licensing Program. Journal of the Association of University Tech- nology Managers XVIII(2):15â28. 104
REFERENCES 105 Mimura, C. 2008. IP management strategies to maximize research impact, collaboration & translation. Presentation at the Institute of Medicine Workshop on Breakthrough Busi- ness Models, June 23, 2008, Washington, DC. Mowatt, M. 2008. Agreements for research and materials sharing. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Ryan, L. 2008. The Alzheimerâs Disease Neuroimaging Initiative (ADNI): A publicâprivate partnership. Presentation at the Institute of Medicine Workshop on Breakthrough Busi- ness Models, June 23, 2008, Washington, DC. Sharpless, N. E., and R. A. DePinho. 2006. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nature Reviews Drug Discovery 5(9):741â754. Shotwell, S. L. 2007. Patent consolidation and equitable access: PATHâs malaria vaccines. Intellectual property management in health and agricultural innovation: A handbook of best practices, edited by A. Krattiger, R. T. Mahoney, I. Nelsen, J. A. Thomson, A. B. Bennett, K. Satyanarayana, G. D. Graff, C. Fernandez, and S. P. Kowalski. Oxford, UK: MIHR and Davis, CA: PIPRA. Pp. 1789-1796. So, A. 2008. Creating an enabling IP environment for neglected and rare diseases. Presenta- tion at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Sorensen, C. 2008. Innovation in alliances and licensing: Transforming now for the future. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Terry, S. 2008. Genetic Alliance Biobank or herding cats. Presentation at the Institute of Medi- cine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Terry, S. F., P. F. Terry, K. Rauen, J. Uitto, and L. Bercovitch. 2007. Advocacy organizations as research organizations: The PXE International example. Nature Reviews Genetics 8(2):157â164. Wetmore, D. 2008. CFFTâs pipeline approach to CFTR drug discovery and development. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC.